Daiichi Sankyo Europe, GmbH clinical trials

A country office of Daiichi Sankyo

The registry lists 18 studies whose lead sponsor is Daiichi Sankyo Europe, GmbH. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2026.

Studies

Recruiting first, then most recently updated. Showing 18 of 18. All Daiichi Sankyo studies →

• TROPION Breast Respond in 1L TNBCNot yet recruitingNCT07867470

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• DESTINY Breast Respond HER2-(Ultra)Low EuropeRecruitingNCT05945732

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed DyslipidemiaActive, not recruitingNCT04579367

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed DyslipidemiaActive, not recruitingNCT06686615

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)Active, not recruitingNCT05993234

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in EuropeCompletedNCT02943993

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR EventsCompletedNCT04271280

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed DyslipidemiaWithdrawnNCT05798390

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Isolated Systolic Hypertension in the Elderly and Very ElderlyCompletedNCT00751829Phase 3

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®CompletedNCT05546398

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary InterventionCompletedNCT02866175Phase 3

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter AblationCompletedNCT02942576Phase 3

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• The Confirmatory Olmesartan Plaque Regression StudyTerminatedNCT01132768Phase 4

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic SyndromeCompletedNCT00891267Phase 3

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24TerminatedNCT00679484Phase 3

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood PressureCompletedNCT01101009Phase 4

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial ProtectionCompletedNCT00676845Phase 3

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

• Olmesartan Medoxomil Versus Losartan in Elderly and Very ElderlyCompletedNCT00751751Phase 3

  Sponsor listed in the registry: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company